MCG heart scan for dofetilide in atrial fibrillation
Part of Heart & circulation clinical trials.
This study uses a special heart scan (MCG) to check how well the medication dofetilide is working for people with atrial fibrillation and Long QT syndrome. It is designed for patients who are already in the hospital for treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have a confirmed diagnosis of atrial fibrillation and are taking dofetilide in the hospital
- You do not have any metal implants in your chest (like a pacemaker or defibrillator)
- You do not have any patches or devices on your chest that must stay on
- You are able to lie flat and stay still on a bed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks whether a specific MRI-safe 12-lead heart recording (ECG) works correctly during MRI scans. It may help improve how doctors monitor heart rhythm while imaging, especially for people with atrial fibrillation.
This trial uses a special MRI scan to see if heart scarring matches low-voltage areas detected during catheter ablation for atrial fibrillation. If the scan results are consistent, it could help doctors better plan ablation procedures.
This study looks at blood-related “clotting” signs and heart scan results in people with atrial fibrillation (AF) who are getting a catheter ablation. It may help doctors better understand AF and choose treatments more precisely.
This trial uses a special CT scan to measure how much extra fluid is in your heart muscle. It aims to help doctors better understand and treat your atrial fibrillation before you have a procedure called ablation.
This trial studies whether CT scans and heart MRI scans (done around the time of atrial fibrillation ablation) can help care planning and results. It may help your team better understand your heart before and after the procedure.
This trial tests whether giving a higher dose of magnesium (4 grams) compared to a lower dose (2 grams) or a placebo can help control a fast heart rate during atrial fibrillation. It may help patients who are already receiving diltiazem.
Hear when a new Atrial fibrillation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.